A one-time gene therapy for hemophilia B from Australian drugmaker CSL Ltd has been approved by the U.S. Food and Drug Administration, potentially offering a long-term solution for patients with the blood clotting disorder.
Updated COVID-19 boosters offer increased protection against new coronavirus subvariants in people who have previously received up to four doses of the older vaccine, based on data from the first study to assess how the retooled shots are faring in the real world, U.S. officials said on Tuesday.
Dr. Anthony Fauci, the U.S. health official celebrated and vilified as the face of the country's COVID-19 pandemic response, used his final White House briefing on Tuesday to denounce division and promote vaccines.
Owners of social media platforms should consider their personal responsibility regarding health disinformation, and the public should choose reputable sources to trust, White House COVID-19 response coordinator Ashish Jha said on Tuesday.
The sprawling, five-year-long litigation over the U.S. opioid crisis appears to be entering its final phase with finalized agreements by Teva Pharmaceutical Industries Ltd and AbbVie Inc .
Teva Pharmaceutical Industries Ltd and AbbVie Inc have finalized the terms of settlements worth more than $6.6 billion to resolve thousands of lawsuits by U.S. state and local governments over the marketing of opioid painkillers, the companies and lawyers for the governments said Tuesday.
A single dose of the monkeypox vaccine provides 78% protection against the virus, according to data from England released on Tuesday that health officials said was the strongest evidence yet of its effectiveness.
Global vaccine alliance Gavi on Tuesday rejected Novavax's claim that the group had breached an advance purchase agreement to procure 350 million doses of the company's COVID-19 vaccine.
China's financial hub Shanghai said on Tuesday it will tighten rules for people entering the city from Nov. 24 to combat the recent COVID-19 outbreak in the country.
Medtronic Plc on Tuesday lowered its full-year outlook for profit and revenue growth, blaming a stronger dollar and a slower-than-anticipated recovery in supply chain disruptions, sending the medical device maker's shares down nearly 6%.
